The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Table 1
Characteristics of patients included in the study.
Parameters
Value of parameters in the groups
PAPS,
SLE + APS,
SLE,
n = 20
n = 26
n = 39
Mean age, year ± SD
34.0 ± 10.8
40.0 ± 11.8
35.5 ± 13.1
Disease duration, year ± SD
8.1 ± 7.3
16.0 ± 11.6
10.2 ± 10.0
Females/males, n (%)
12 (60)/8 (40)
22 (85)/4 (15)
36 (92)/3 (8)
Disease activity, SLEDAI-index (mean scores ± SD)
-
19.4 ± 8.6
20.0 ± 12.1
Thrombosis in past history, n (%)
16 (80)
18 (69)
-
Obstetrical morbidity, n (%)
5 (20)
11 (42.3)
-
Therapy at the time of study inclusion
GCs, n (%)
0
23 (89)
21 (54)
Anticoagulants (LMWH, VKA), n (%)
20 (100)
26 (100)
3 (7.7)
LDASA, n (%)
20 (100)
26 (100)
14 (36)
NSAID, n (%)
1 (5)
9 (34.6)
10 (25.6)
Patients [n (%)] who did not receive GCs, ACs, LDASA, NSAID+LDASA (comparison group) during 6 months or more
-
-
12 (30.8)
Note: SD: standard deviations; GCs: glucocorticoids; LDASA: low-dose acetylsalicylic acid; NSAID: nonsteroidal anti-inflammatory drugs; ACs: anticoagulants; LMWH: low-molecular-weight heparin; VKA: vitamin K antagonist. The percentage was calculated from the number of women who had a pregnancy during the disease. P < 0.005 compared to those in PAPS patients.
